tumor necrosis factor blocker Latest Research Papers

P023 Disseminated Histoplasmosis in a Patient with Crohn's Disease Under Tumor Necrosis Factor Blocker Therapy: An Unusual Case

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000613060.27726.48 ◽

2019 ◽

Vol 114 (1) ◽

pp. S6-S7

Author(s):

Sandro Ferreira ◽

Fernando Jorge Nóbrega ◽

Roberta Araujo ◽

Rodrigo Santana ◽

Leandra Ramalho ◽

...

Keyword(s):

Crohn’S Disease ◽

Tumor Necrosis Factor ◽

Crohn's Disease ◽

Tumor Necrosis ◽

Unusual Case ◽

Blocker Therapy ◽

Tumor Necrosis Factor Blocker ◽

Disseminated Histoplasmosis ◽

Necrosis Factor

Download Full-text

Effects of Tumor Necrosis Factor Blocker on Salicylate-Induced Tinnitus in Mice

The International Tinnitus Journal ◽

10.5935/0946-5448.20170006 ◽

2017 ◽

Vol 21 (1) ◽

Cited By ~ 2

Author(s):

Juen-Haur Hwang ◽

David Chang-Wei Huang ◽

Yin-Chang Lu ◽

Wei-Shiung Yang ◽

Tien-Chen Liu

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text

Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data

Joint Bone Spine ◽

10.1016/j.jbspin.2015.09.006 ◽

2016 ◽

Vol 83 (5) ◽

pp. 569-572 ◽

Cited By ~ 13

Author(s):

Tae-Jong Kim ◽

Ji-Hui Shin ◽

Suna Kim ◽

Il-Hoon Sung ◽

Seunghun Lee ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Radiographic Progression ◽

Observation Study ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718524885.793498401 ◽

2014 ◽

Author(s):

David Daikh

Keyword(s):

Clinical Trial ◽

Ankylosing Spondylitis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Blocker ◽

Different Response ◽

Necrosis Factor

Download Full-text

National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans

Journal of Medical Economics ◽

10.3111/13696998.2013.856314 ◽

2013 ◽

Vol 17 (1) ◽

pp. 1-10 ◽

Cited By ~ 12

Author(s):

Amie T. Joyce ◽

Shravanthi R. Gandra ◽

Kathleen M. Fox ◽

Timothy W. Smith ◽

Michael W. Pill

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Dose Escalation ◽

Tumor Necrosis ◽

Health Plans ◽

Blocker Therapy ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text

SAT0143 Tumor necrosis factor-blocker use in us managed care: Utilization and dosing patterns among rheumatoid arthritis patients:

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.3090 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 520.1-520

Author(s):

M. Fisher ◽

C. Watson ◽

K.M. Fox ◽

Y.-W. Chen ◽

S.R. Gandra

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Tumor Necrosis ◽

Care Utilization ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor ◽

Dosing Patterns

Download Full-text

Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting

Advances in Therapy ◽

10.1007/s12325-013-0034-3 ◽

2013 ◽

Vol 30 (5) ◽

pp. 517-527 ◽

Cited By ~ 8

Author(s):

Steven W. Blume ◽

Kathleen M. Fox ◽

George Joseph ◽

Chien-Chia Chuang ◽

Jessy Thomas ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Dose Escalation ◽

Tumor Necrosis ◽

Pharmacy Benefit Management ◽

Pharmacy Benefit ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text

Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients

Joint Bone Spine ◽

10.1016/j.jbspin.2012.02.006 ◽

2012 ◽

Vol 79 (5) ◽

pp. 520-521

Author(s):

Sanae Ali Ou Alla ◽

Cedric Lukas ◽

Najia Hajjaj-Hassouni ◽

René Marc Flipo ◽

Bernard Combe ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Blocker Therapy ◽

Subcutaneous Tumor ◽

Tumor Necrosis Factor Blocker ◽

Das28 Remission ◽

Necrosis Factor

Download Full-text

PMS69 Tumor Necrosis Factor Blocker Dose Escalation among Biologic Naïve Rheumatoid Arthritis (RA) Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation

Value in Health ◽

10.1016/j.jval.2012.03.258 ◽

2012 ◽

Vol 15 (4) ◽

pp. A46

Author(s):

M. Bonafede ◽

S.R. Gandra ◽

K.M. Fox ◽

K. Wilson

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Dose Escalation ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Blocker ◽

Care Plans ◽

Therapy Initiation ◽

Necrosis Factor

Download Full-text

PMS16 Cost of Tumor Necrosis Factor Blocker Per Treated Psoriatic Arthritis Patient Using Drug Utilization Data from a US Managed Care Population

Value in Health ◽

10.1016/j.jval.2012.03.205 ◽

2012 ◽

Vol 15 (4) ◽

pp. A36

Author(s):

M. Bonafede ◽

C. Watson ◽

S.R. Gandra ◽

N. Princic ◽

K.M. Fox

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Drug Utilization ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Blocker ◽

Utilization Data ◽

Necrosis Factor

Download Full-text

tumor necrosis factor blocker
Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

P023 Disseminated Histoplasmosis in a Patient with Crohn's Disease Under Tumor Necrosis Factor Blocker Therapy: An Unusual Case

Effects of Tumor Necrosis Factor Blocker on Salicylate-Induced Tinnitus in Mice

Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data

Faculty Opinions recommendation of Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.

National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans

SAT0143 Tumor necrosis factor-blocker use in us managed care: Utilization and dosing patterns among rheumatoid arthritis patients:

Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting

Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients

PMS69 Tumor Necrosis Factor Blocker Dose Escalation among Biologic Naïve Rheumatoid Arthritis (RA) Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation

PMS16 Cost of Tumor Necrosis Factor Blocker Per Treated Psoriatic Arthritis Patient Using Drug Utilization Data from a US Managed Care Population

Export Citation Format

tumor necrosis factor blockerRecently Published Documents

TOTAL DOCUMENTS

H-INDEX

P023 Disseminated Histoplasmosis in a Patient with Crohn's Disease Under Tumor Necrosis Factor Blocker Therapy: An Unusual Case

Effects of Tumor Necrosis Factor Blocker on Salicylate-Induced Tinnitus in Mice

Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data

Faculty Opinions recommendation of Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.

National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans

SAT0143 Tumor necrosis factor-blocker use in us managed care: Utilization and dosing patterns among rheumatoid arthritis patients:

Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting

Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients

PMS69 Tumor Necrosis Factor Blocker Dose Escalation among Biologic Naïve Rheumatoid Arthritis (RA) Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation

PMS16 Cost of Tumor Necrosis Factor Blocker Per Treated Psoriatic Arthritis Patient Using Drug Utilization Data from a US Managed Care Population

tumor necrosis factor blocker
Recently Published Documents